Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation-Reference-Cited by-同舟云学术

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Published:2017-04-12 Issue:385 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Allen Elizabeth¹^ORCID,Jabouille Arnaud²^ORCID,Rivera Lee B.²^ORCID,Lodewijckx Inge¹,Missiaen Rindert¹^ORCID,Steri Veronica²,Feyen Kevin¹,Tawney Jaime²,Hanahan Douglas³,Michael Iacovos P.³^ORCID,Bergers Gabriele¹²^ORCID

Affiliation:

1. Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-Center for Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.

2. Brain Tumor Research Center, Department of Neurological Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.

3. Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Station 19, 1015 Lausanne, Switzerland.

Abstract

Efficacy of antiangiogenic immunotherapy is associated with intratumoral formation of high endothelial venules.

Funder

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference70 articles.

1. Hallmarks of Cancer: The Next Generation

2. The parallel lives of angiogenesis and immunosuppression: cancer and other tales

3. Combination cancer immunotherapy and new immunomodulatory targets